Intellectual Property India Publishes Patent Application for 'Cross-Specific Antigen Binding Proteins (Abp) Targeting Leukocyte Immunoglobulin-Like Receptor Subfamily B1 (Lilrb1) And Lilrb2, Combinations And Uses Thereof' Filed by Iomx Therapeutics Ag

MUMBAI, India, Aug. 22 -- Intellectual Property India has published a patent application (202517069766 A) filed by Iomx Therapeutics Ag, Martinsried, Germany, on July 22, for 'cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof.'

Inventor(s) include Zantow, Jonas; Schilz, Jonas; Friedrich, Simone; Hartl, Christina; Milde, Ronny; Aigner, Maximilian; and Sudan, Kritika.

The application for the patent was published on Aug. 22, under issue no. 34/2025.

According to the abstract released by the Intellectual Property India: "The invention relates to antigen binding proteins, such as antibodies, that bind to both leukocyte immunoglobulin-like receptor subfamily B1 (LILRB1) and LILRB2 while not binding to, or binding with significantly less affinity to, leukocyte immunoglobulin-like receptor subfamily A (LILRA), which can also inhibit the interaction between LILRB1 and/or LILRB2 and a natural ligand of LILRB receptors (interacting proteins, such as HLA-G) on immune cells and the inhibition of such interaction can reduce immune cell suppression and thereby support anti-infection and anti-tumour immune responses in a subject suffering from such diseases. In particular, the invention provides products, compositions and methods for treating diseases using antigen binding proteins of LILRB1 and/or LILRB2, especially antigen binding proteins which while, preferably specifically, binding to LILRB1 and LILRB2, such as antigen binding proteins that further do not bind to, or bind with less affinity to, one or more LILRA receptor proteins (such as LILRA1 and/or LILRA3). Also provided are methods of reducing the immune suppression of cells involved with a cell-mediated immune response, and/or methods for treating infective- and/or proliferative diseases, using an LILRB1 and/or LILRB2 antigen binding protein such as an antibody binding to both LILRB1 and/or LILRB2, as well as certain related aspects including detection, diagnostic and screening methods."

The patent application was internationally filed on Dec. 22, 2023, under International application No.PCT/EP2023/087744.

Disclaimer: Curated by HT Syndication.